CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Aug 7, 2025

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -